Sagimet Biosciences Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Foster City, CA
SGMT chart
What traders are saying about $SGMT
Latest postsSagimet Biosciences Inc. news
- SGMT: Denifanstat’s U.S. phase III is underway, with primary results targeted by end-2027
TradingView ·
- Sagimet Biosciences at guggenheim healthcare conference: acne pivot gains traction By Investing.com
Investing.com India ·
- Press Releases about Omeros Corporation - Common Stock (Nasdaq:OMER)
FinancialContent ·
- Understanding Momentum Shifts in (SGMT)
Stock Traders Daily ·
- Sagimet Biosciences Series A (SGMT) Stock Price, News & Analysis
Stock Titan ·
- Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
Yahoo Finance ·
- Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
Yahoo Finance ·
- Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
Yahoo Finance ·
- After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
Yahoo Finance ·
- Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
Yahoo Finance ·
- Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Yahoo Finance ·
Sagimet Biosciences Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $2.0M | – |
| Net income | -$51.0M | -$45.6M | -$27.9M | -$30.5M |
| Diluted EPS | $-1.58 | $-1.45 | $-2.66 | $-165.20 |
| Total assets (year end) | $116.5M | $160.3M | $96.7M | $33.0M |
| Cash and equivalents (year end) | $35.0M | $75.8M | $75.1M | $158,000 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Sagimet Biosciences Inc.
- Ticker
- SGMT (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Foster City, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1400118
- Former names
- 3-V Biosciences, Inc.
Frequently asked questions
What exchange is Sagimet Biosciences Inc. listed on?
Sagimet Biosciences Inc. trades on the Nasdaq under the ticker symbol SGMT.
What industry is Sagimet Biosciences Inc. in?
Sagimet Biosciences Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Sagimet Biosciences Inc. headquartered?
Sagimet Biosciences Inc.'s business address on file with the SEC is in Foster City, CA.
When does Sagimet Biosciences Inc.'s fiscal year end?
Sagimet Biosciences Inc.'s fiscal year ends on December 31.
How much revenue did Sagimet Biosciences Inc. report?
Sagimet Biosciences Inc. reported $2.0M in revenue for calendar year 2023, according to its SEC filings.